Inositol: history of an effective therapy for Polycystic Ovary Syndrome

被引:2
|
作者
Bizzarri, M. [1 ]
Carlomagno, G. [2 ]
机构
[1] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy
[2] LoLiPharma Srl, Dept Med, Rome, Italy
关键词
Inositol; Polycistic ovary syndrome; PCOS; D-CHIRO-INOSITOL; SPERM INJECTION CYCLES; IMPROVE OOCYTE QUALITY; IN-VITRO FERTILIZATION; DOUBLE-BLIND TRIAL; INSULIN-RESISTANCE; MYOINOSITOL SUPPLEMENTATION; OVULATION INDUCTION; OVERWEIGHT PATIENTS; NONOBESE PATIENTS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inositol is a physiological compound belonging to the sugar family. The two inositol stereoisomers, myo-inositol and D-chiroinositol are the two main stereisomers present in our body. Myo-inositol is the precursor of inositol triphosphate, a second messenger regulating many hormones such as TSH, FSH and insulin. D-chiroinositol is synthetized by an insulin dependent epimerase that converts myo-inositol into D-chiro-inositol. Polycistic Ovary Syndrome (PCOS) is a metabolic and hormonal disorder and a common cause of infertility. Insulin resistance and the consequent hyperinsulinaemia contribute to hyperandrogenism development, typical marker of PCOS. In these patients myo and/or D-chiro-inositol administration improves insulin sensivity while only myo-inositol is a quality marker for oocytes evaluation. Myo-inositol produces second messengers for FSH and glucose uptake, while D-chiroinositol provides second messengers promoting glucose uptake and glycogen synthesis. The physiological ratio of these two isomers is 40:1 (MI/DCI) and seems to be an optimal approach for the treatment of PCOS disorders.
引用
收藏
页码:1896 / 1903
页数:8
相关论文
共 50 条
  • [1] Inositol for Polycystic Ovary Syndrome (PCOS)
    Seifert-Klauss, Vanadin
    GYNAKOLOGISCHE ENDOKRINOLOGIE, 2024, 22 (03): : 230 - 232
  • [2] Inositol for subfertile women with polycystic ovary syndrome
    Showell, Marian G.
    Mackenzie-Proctor, Rebecca
    Jordan, Vanessa
    Hodgson, Ruth
    Farquhar, Cindy
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (12):
  • [3] Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome
    Unfer, Vittorio
    Porcaro, Giuseppina
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (05) : 623 - 631
  • [4] History of discovery of polycystic ovary syndrome
    Szydlarska, Dorota
    Machaj, Malgorzata
    Jakimiuk, Artur
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 26 (03): : 555 - 558
  • [5] Inositol treatment for psychological symptoms in Polycystic Ovary Syndrome women
    Cantelmi, T.
    Lambiase, E.
    Unfer, V. R.
    Gambioli, R.
    Unfer, V
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (05) : 2383 - 2389
  • [6] The role of inositol deficiency in the etiology of polycystic ovary syndrome disorders
    Jakimiuk, Artur J.
    Szamatowicz, Jacek
    GINEKOLOGIA POLSKA, 2014, 85 (01) : 54 - 57
  • [7] Inositol effects on ovulation induction in patients with polycystic ovary syndrome
    Papaleo, Enrico
    FERTILITY AND STERILITY, 2011, 95 (07) : E47 - E47
  • [8] Exercise therapy in polycystic ovary syndrome
    Hoeger, Kathgeen M.
    SEMINARS IN REPRODUCTIVE MEDICINE, 2008, 26 (01) : 93 - 100
  • [9] Comments on the role of inositol supplementation in patients with polycystic ovary syndrome
    Rizzo, Pietro
    Raffone, Emanuele
    FERTILITY AND STERILITY, 2011, 95 (07) : E48 - E48
  • [10] Metformin therapy in polycystic ovary syndrome
    Jakimiuk, Artur J.
    GINEKOLOGIA POLSKA, 2008, 79 (01) : 8 - 11